VA-HILTON
Well-positioned to emerge from the pandemic stronger than ever, Hilton delivered a record year of development achievements. Already one of the world’s largest hotel companies, Hilton opened 414 properties, adding more than 67,100 rooms to its system, further emphasizing the scale, presence and leading brands of the company’s global portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220121005394/en/
“After a year of recovery and growth, it has been incredible to witness the resiliency of the travel industry and our team’s ability to embrace change while serving more guests in more hotels around the world,” said Chris Nassetta, President and CEO, Hilton. “We believe the desire to travel, experience new cultures and connect with others is core to the human experience. I can speak for all of us at Hilton when I say we’re looking forward to welcoming our guests and helping them make new memories in 2022.”
Global development efforts have continued to show strong performance through the pandemic. Hilton ended 2021 with more than 6,800 hotels across 18 brands in six continents, with robust net unit growth of 5.6%. The company’s development pipeline includes nearly 2,670 hotels representing approximately 408,000 rooms, nearly half of which are under construction.
“Hilton’s development continues to be a key performance indicator of how well-positioned we are for the long-term,” said Kevin Jacobs, CFO and president, global development, Hilton. “Hotel owners choose to work with us because of our premium commercial performance. With our capital light business model, we strive to maximize net unit growth, while continuing to deliver value for all our stakeholders.”
Celebrating A Year of Market and Category Milestones
- Historic Las Vegas Development: Hilton notably expanded its presence in the Las Vegas market, which is now home to 13 brands, including all three of our luxury brands, 36 hotels and more than 12,000 rooms. In June 2021, Hilton and Genting Group partnered in the historic opening of Resorts World Las Vegas , the largest multi-brand resort in Hilton’s history, integrating three premium brands – the largest Conrad Hotels & Resorts property in the world, one of the first LXR Hotels & Resorts locations in the U.S. and a marquee Hilton Hotels & Resorts hotel. Additionally, Curio Collection by Hilton re-emerged in Las Vegas with the introduction of Virgin Hotels Las Vegas, Curio Collection by Hilton .
- Significant All-Inclusive Expansion: Hilton’s all-inclusive portfolio expanded in 2021 with openings in the Caribbean and Latin America, including Hilton Cancun, an All-Inclusive Resort, Hilton Vallarta Riviera All-Inclusive Resort , Mangrove Beach Corendon Curaçao All-Inclusive Resort, Curio Collection by Hilton and The Yucatan Playa del Carmen All-Inclusive Resort, Tapestry Collection by Hilton .
- Hilton’s lifestyle brands gained momentum in Europe, the Middle East & Africa (EMEA) and Brazil. Canopy by Hilton made its debuts in France, UK and Spain. Motto by Hilton announced plans to open its first hotel in Europe with Motto Rotterdam Blaak in the Netherlands in 2022. Additionally, Brazil welcomed two Hilton brands with the debuts of Canopy by Hilton Sao Paulo Jardins and Almenat Hotel, Tapestry Collection by Hilton .
- Asia Pacific Growth: Hilton Nagasaki ’s flagship opening marked the company’s 500th hotel in Asia Pacific, while Hilton Lanzhou City Center ’s opening marked the 400th hotel in the Greater China and Mongolia region.
- Washington, D.C. Expansion: The company introduced its 25th hotel within the portfolio in Washington, D.C. with the debut of Hilton Washington DC Capitol Hill .
Recognizing Year of “Firsts” for the Brand Portfolios with Market Expansions
- Waldorf Astoria Hotels & Resorts expanded the brand’s West Coast presence with the opening of Waldorf Astoria Monarch Beach Resort & Club in Dana Pointe, California and signed a milestone management agreement with Orix Real Estate Corporation to expand the brand into Osaka, Japan in 2025.
- Management agreement was signed for the first Conrad Hotels & Resorts property in California with Conrad Los Angeles (opening Spring 2022) as well as the first in Tulum with Conrad Tulum Riviera Maya .
- LXR Hotels & Resorts was introduced in Africa and the Indian Ocean with Mango House Seychelles and in Asia Pacific with ROKU KYOTO, LXR Hotels & Resorts .
- Signia by Hilton debuted with the conversion and rebrand of Signia by Hilton Orlando Bonnet Creek . Additionally, Signia by Hilton Atlanta broke ground at Georgia World Congress Center.
- Curio Collection by Hilton surpassed 100 properties worldwide with the opening of Sable at Navy Pier Chicago, Curio Collection by Hilton .
- DoubleTree by Hilton extended its international reach to its 50th trading market with the opening of DoubleTree by Hilton Frankfurt Niederrad, the brand’s first in Germany.
- Tapestry Collection by Hilton introduced properties in Europe and the Chinese Mainland, including Atocha Hotel Madrid, Tapestry Collection by Hilton and Hollick Hotel Wen’an, Tapestry Collection by Hilton .
- Motto by Hilton announced plans to open its first hotels in Europe and Latin America in 2022 with Motto Rotterdam Blaak in the Netherlands and Motto Tulum in Mexico.
- Hilton Garden Inn entered into Australasia, South Korea, Thailand and Indonesia’s capital city Jakarta with Hilton Garden Inn Albany , Hilton Garden Inn Seoul Gangnam , Hilton Garden Inn Phuket Bang Tao and Hilton Garden Inn Jakarta Taman Palem , respectively. Additionally, the brand launched its large-scale franchise model in China , welcoming investors and independent owners to explore franchising opportunities.
- Hampton by Hilton celebrated milestones throughout the year, surpassing 2,700 open hotels and expanding into Ireland, Uzbekistan and Qatar, as well as the Cayman Islands with Hampton by Hilton Grand Cayman . Hampton also remains the fastest-growing international hotel brand in China, marking 200 open hotels, with an additional 600 signed development deals within the country. Additionally, starting 2022 strong, the brand was recognized for the 13th year in a row as the No. 1 hotel franchise by Entrepreneur ’s Franchise 500® , tying the record for most total No. 1 rankings in the Hotels & Motels category.
- Tru by Hilton opened its 200th hotel, adding nearly 100 hotels during the pandemic, and announced expansion into the Caribbean and Latin America, with developments in Brazil, Costa Rica, Dominican Republic, Mexico and Puerto Rico.
- Homewood Suites by Hilton unveiled a comprehensive brand refresh with a game-changing, all-new prototype – ‘Prototype 10.0’ – designed to offer added value and versatility for owners and developers, while exceeding the needs of guests who want the comforts of home.
- Home2 Suites by Hilton became one of the fastest-growing hotel brands as it reached 500 open properties in just 10 years and touts the largest pipeline in the U.S., with 437 properties in development. The brand also debuted in China , with the opening of the first of 1,000 Home2 Suites by Hilton properties in the region.
In addition to development milestones, Hilton continued to innovate to meet the evolving needs of travelers with the introduction of industry-leading programs and products, such as Confirmed Connecting Rooms by Hilton and Hilton Honors Digital Key Share , and the evolution of brand standards, including expanding its pet-friendly offerings . To learn more, visit newsroom.hilton.com .
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,800 properties and more than 1 million rooms, in 122 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2021 World’s Best Workplaces list and been recognized as a global leader on the Dow Jones Sustainability Indices for five consecutive years. In 2021, in addition to opening more than one hotel a day, Hilton introduced several industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the nearly 128 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy. With the free Hilton Honors app , guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
